- Sepsis Awareness: Advancing Timely Diagnosis
- Supporting Ebola Response: Rapid Diagnostics and Global Expertise
- Progress Toward a More Sustainable Future
News
bioMérieux, a world leader in the field of in vitro diagnostics, announced that its BIOFIRE® Respiratory 2.1 plus (RP2.1plus) Panel and BIOFIRE® FILMARRAY® Pneumonia plus (PNplus) Panel have received CE marking under the IVDR* as Class D in vitro diagnostic devices, the highest risk classification under the regulation. The classification is driven by the inclusion of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) on both test menus.
Swipe for more stories
-
Surviving Sepsis: How Diagnostics Can Help Improve Outcomes When Every Hour Matters
For patients at risk of sepsis, time matters. Faster diagnostic information can help healthcare teams identify the cause of infection sooner, supporting earlier better-informed care decisions. -
First-Half 2026 Results
bioMérieux's Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26. -
bioMérieux Launches PCR Testing Solution to Verify Probiotic Species in Dietary Supplements Manufacturing
With GENE-UP® PROBIOTIC SPECIES ID, bioMérieux introduces a first-of-its-kind commercialized species-level identification PCR solution for in-house quality control teams and external laboratory partners.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19